Article: Curis Issued U.S. Patent Covering Hedgehog Pathway Agonists.

CAMBRIDGE, Mass. -- Curis, Inc. (NASDAQ: CRIS), a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, today announced that it has been issued U.S. patent 7,115,653, entitled "Small Organic Molecule Regulators of Cell Proliferation." The claims of this patent cover specific small molecule compounds that are activators, or agonists, of the Hedgehog signaling pathway, as well as pharmaceutical compositions and preparations containing specific Hedgehog agonist compounds. Curis believes that the claims of this patent provide additional depth to its existing intellectual property position surrounding Hedgehog agonist ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!